PDCD1 and ovarian carcinoma: Other studies shown that combining anti-PD-1 and glucocorticoid-induced tumor necrosis factor receptor family-related protein (GITR) monoclonal antibodies significantly inhibit peritoneal lesions in ovarian cancer, with one-fifth of mice not developing metastases, whereas monotherapy showed minimal effects (37).